These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 27382168)

  • 1. pH-degradable imidazoquinoline-ligated nanogels for lymph node-focused immune activation.
    Nuhn L; Vanparijs N; De Beuckelaer A; Lybaert L; Verstraete G; Deswarte K; Lienenklaus S; Shukla NM; Salyer AC; Lambrecht BN; Grooten J; David SA; De Koker S; De Geest BG
    Proc Natl Acad Sci U S A; 2016 Jul; 113(29):8098-103. PubMed ID: 27382168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent anti-viral vaccine adjuvant based on pH-degradable nanogels with covalently linked small molecule imidazoquinoline TLR7/8 agonist.
    Nuhn L; Van Hoecke L; Deswarte K; Schepens B; Li Y; Lambrecht BN; De Koker S; David SA; Saelens X; De Geest BG
    Biomaterials; 2018 Sep; 178():643-651. PubMed ID: 29573820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses.
    Dowling DJ; Scott EA; Scheid A; Bergelson I; Joshi S; Pietrasanta C; Brightman S; Sanchez-Schmitz G; Van Haren SD; Ninković J; Kats D; Guiducci C; de Titta A; Bonner DK; Hirosue S; Swartz MA; Hubbell JA; Levy O
    J Allergy Clin Immunol; 2017 Nov; 140(5):1339-1350. PubMed ID: 28343701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control over Imidazoquinoline Immune Stimulation by pH-Degradable Poly(norbornene) Nanogels.
    Kockelmann J; Stickdorn J; Kasmi S; De Vrieze J; Pieszka M; Ng DYW; David SA; De Geest BG; Nuhn L
    Biomacromolecules; 2020 Jun; 21(6):2246-2257. PubMed ID: 32255626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Squaric Ester-Based, pH-Degradable Nanogels: Modular Nanocarriers for Safe, Systemic Administration of Toll-like Receptor 7/8 Agonistic Immune Modulators.
    Huppertsberg A; Kaps L; Zhong Z; Schmitt S; Stickdorn J; Deswarte K; Combes F; Czysch C; De Vrieze J; Kasmi S; Choteschovsky N; Klefenz A; Medina-Montano C; Winterwerber P; Chen C; Bros M; Lienenklaus S; Sanders NN; Koynov K; Schuppan D; Lambrecht BN; David SA; De Geest BG; Nuhn L
    J Am Chem Soc; 2021 Jul; 143(26):9872-9883. PubMed ID: 34166595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent and Prolonged Innate Immune Activation by Enzyme-Responsive Imidazoquinoline TLR7/8 Agonist Prodrug Vesicles.
    Wang B; Van Herck S; Chen Y; Bai X; Zhong Z; Deswarte K; Lambrecht BN; Sanders NN; Lienenklaus S; Scheeren HW; David SA; Kiessling F; Lammers T; De Geest BG; Shi Y
    J Am Chem Soc; 2020 Jul; 142(28):12133-12139. PubMed ID: 32524819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy.
    Kim H; Niu L; Larson P; Kucaba TA; Murphy KA; James BR; Ferguson DM; Griffith TS; Panyam J
    Biomaterials; 2018 May; 164():38-53. PubMed ID: 29482062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A TLR7/8 Agonist-Including DOEPC-Based Cationic Liposome Formulation Mediates Its Adjuvanticity Through the Sustained Recruitment of Highly Activated Monocytes in a Type I IFN-Independent but NF-κB-Dependent Manner.
    Auderset F; Belnoue E; Mastelic-Gavillet B; Lambert PH; Siegrist CA
    Front Immunol; 2020; 11():580974. PubMed ID: 33262759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the adjuvant effect of agonists of toll-like receptor 4 and 7/8 in a vaccine against leishmaniasis in BALB/c mice.
    Rostamian M; Niknam HM
    Mol Immunol; 2017 Nov; 91():202-208. PubMed ID: 28963929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists.
    Rajagopal D; Paturel C; Morel Y; Uematsu S; Akira S; Diebold SS
    Blood; 2010 Mar; 115(10):1949-57. PubMed ID: 20065291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01.
    Wilkinson A; Lattmann E; Roces CB; Pedersen GK; Christensen D; Perrie Y
    J Control Release; 2018 Dec; 291():1-10. PubMed ID: 30291987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of the Immunostimulatory Activity of a TLR7 Ligand by Conjugation to Polysaccharides.
    Shinchi H; Crain B; Yao S; Chan M; Zhang SS; Ahmadiiveli A; Suda Y; Hayashi T; Cottam HB; Carson DA
    Bioconjug Chem; 2015 Aug; 26(8):1713-23. PubMed ID: 26193334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyaluronic Acid Conjugates of TLR7/8 Agonists for Targeted Delivery to Secondary Lymphoid Tissue.
    Yoo E; Salyer ACD; Brush MJH; Li Y; Trautman KL; Shukla NM; De Beuckelaer A; Lienenklaus S; Deswarte K; Lambrecht BN; De Geest BG; David SA
    Bioconjug Chem; 2018 Aug; 29(8):2741-2754. PubMed ID: 29969553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.
    Vasilakos JP; Tomai MA
    Expert Rev Vaccines; 2013 Jul; 12(7):809-19. PubMed ID: 23885825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
    Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
    J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of novel synthetic TLR7/8 agonists as vaccine adjuvants.
    Smith AJ; Li Y; Bazin HG; St-Jean JR; Larocque D; Evans JT; Baldridge JR
    Vaccine; 2016 Aug; 34(36):4304-12. PubMed ID: 27402566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acidic pH-responsive polymer nanoparticles as a TLR7/8 agonist delivery platform for cancer immunotherapy.
    Kim H; Sehgal D; Kucaba TA; Ferguson DM; Griffith TS; Panyam J
    Nanoscale; 2018 Nov; 10(44):20851-20862. PubMed ID: 30403212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent Lymphatic Translocation and Spatial Control Over Innate Immune Activation by Polymer-Lipid Amphiphile Conjugates of Small-Molecule TLR7/8 Agonists.
    De Vrieze J; Louage B; Deswarte K; Zhong Z; De Coen R; Van Herck S; Nuhn L; Kaas Frich C; Zelikin AN; Lienenklaus S; Sanders NN; Lambrecht BN; David SA; De Geest BG
    Angew Chem Int Ed Engl; 2019 Oct; 58(43):15390-15395. PubMed ID: 31397948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective anti-mycobacterial T cell responses through exquisite in vivo activation of vaccine-targeted dendritic cells.
    Kamath AT; Valenti MP; Rochat AF; Agger EM; Lingnau K; von Gabain A; Andersen P; Lambert PH; Siegrist CA
    Eur J Immunol; 2008 May; 38(5):1247-56. PubMed ID: 18412160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymph-Node-Targeted Immune Activation by Engineered Block Copolymer Amphiphiles-TLR7/8 Agonist Conjugates.
    Van Herck S; Deswarte K; Nuhn L; Zhong Z; Portela Catani JP; Li Y; Sanders NN; Lienenklaus S; De Koker S; Lambrecht BN; David SA; De Geest BG
    J Am Chem Soc; 2018 Oct; 140(43):14300-14307. PubMed ID: 30277761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.